DE1695772C3 - l-(p-Hydroxyphenyl)-2-(4-benzylpiperidino)-propan-l-ol und Verfahren zu seiner Herstellung - Google Patents

l-(p-Hydroxyphenyl)-2-(4-benzylpiperidino)-propan-l-ol und Verfahren zu seiner Herstellung

Info

Publication number
DE1695772C3
DE1695772C3 DE1695772A DE1695772A DE1695772C3 DE 1695772 C3 DE1695772 C3 DE 1695772C3 DE 1695772 A DE1695772 A DE 1695772A DE 1695772 A DE1695772 A DE 1695772A DE 1695772 C3 DE1695772 C3 DE 1695772C3
Authority
DE
Germany
Prior art keywords
effect
propan
hydroxyphenyl
isoxsuprine
benzylpiperidino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DE1695772A
Other languages
German (de)
English (en)
Other versions
DE1695772A1 (de
DE1695772B2 (de
Inventor
Claude Louis Clement Carron
Maurice Claude Ernest Carron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LABORATOIRES ROBERT ET CARRIERE PARIS SA
Original Assignee
LABORATOIRES ROBERT ET CARRIERE PARIS SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LABORATOIRES ROBERT ET CARRIERE PARIS SA filed Critical LABORATOIRES ROBERT ET CARRIERE PARIS SA
Publication of DE1695772A1 publication Critical patent/DE1695772A1/de
Publication of DE1695772B2 publication Critical patent/DE1695772B2/de
Application granted granted Critical
Publication of DE1695772C3 publication Critical patent/DE1695772C3/de
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE1695772A 1966-09-27 1967-09-07 l-(p-Hydroxyphenyl)-2-(4-benzylpiperidino)-propan-l-ol und Verfahren zu seiner Herstellung Expired DE1695772C3 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR77770A FR5733M (cg-RX-API-DMAC7.html) 1966-09-27 1966-09-27

Publications (3)

Publication Number Publication Date
DE1695772A1 DE1695772A1 (de) 1972-02-17
DE1695772B2 DE1695772B2 (de) 1973-11-22
DE1695772C3 true DE1695772C3 (de) 1974-06-20

Family

ID=8617916

Family Applications (1)

Application Number Title Priority Date Filing Date
DE1695772A Expired DE1695772C3 (de) 1966-09-27 1967-09-07 l-(p-Hydroxyphenyl)-2-(4-benzylpiperidino)-propan-l-ol und Verfahren zu seiner Herstellung

Country Status (5)

Country Link
US (1) US3509164A (cg-RX-API-DMAC7.html)
BE (1) BE878876Q (cg-RX-API-DMAC7.html)
DE (1) DE1695772C3 (cg-RX-API-DMAC7.html)
FR (1) FR5733M (cg-RX-API-DMAC7.html)
GB (1) GB1159449A (cg-RX-API-DMAC7.html)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2067187B (en) * 1979-12-07 1983-11-30 Cosmos Enterprise Process for the preparation of 1-(4-hydroxyphenyl)-2-(4-benzylpiperidino)-1-propanol and acid addition salts thereof
FR2503705A1 (fr) * 1981-04-14 1982-10-15 Synthelabo Derives de phenethanolamine, leur preparation et leur application en therapeutique
KR840001829A (ko) * 1981-10-30 1984-06-07 스즈끼 시개끼 새로운 이펜프로딜을 함유하는 정제의 제조방법
GR78370B (cg-RX-API-DMAC7.html) * 1981-12-24 1984-09-26 Delalande Sa
FR2534580A1 (fr) * 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
WO1987000433A1 (fr) * 1985-07-24 1987-01-29 Grelan Pharmaceutical Co., Ltd. Agent ameliorant la circulation
SK279476B6 (sk) * 1989-05-17 1998-11-04 Pfizer Deriváty 2-piperidino a 2-pyrolidino-1-alkanolov a
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
FR2654341B1 (fr) * 1989-11-14 1994-09-23 Synthelabo Utilisation d'ifenprodil et de ses derives pour la fabrication de medicaments antipsychotiques.
WO1991012005A1 (en) * 1990-02-06 1991-08-22 Pfizer Inc. Neuroprotective 3-piperidino-4-hydroxychroman derivatives and analogs
US5306723A (en) * 1990-05-10 1994-04-26 Pfizer Inc. Neuroprotective indolone and related derivatives
FI934566A7 (fi) * 1991-04-18 1993-10-15 Pfizer Fenoli-2-piperidino-1-alkanolien prodrugesterit
US5710168A (en) * 1991-10-23 1998-01-20 Pfizer Inc. 2-piperidino-1-alkanol derivatives as neuroprotective agents
US5527912A (en) * 1991-10-23 1996-06-18 Pfizer Inc. Intermediates for 2-piperidino-1-alkanol derivatives
US6255322B1 (en) 1992-06-19 2001-07-03 Pfizer Inc. 2-(4-hydroxypiperidino)-1-alkanol derivatives as antiischemic agents
US5436255A (en) * 1992-07-23 1995-07-25 Pfizer Inc. Method of treating diseases susceptable to treatment by blocking NMDA-receptors
KR950704298A (ko) * 1992-10-30 1995-11-17 알렌 제이.스피겔 신경보호성 3,4-디하이드로-2(1h)-퀴놀론 화합물(neuroprotective 3,4-dihydro-2(1h)-quinolone compounds)
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
WO1995020587A1 (en) * 1994-01-31 1995-08-03 Pfizer Inc. Neuroprotective chroman compounds
FR2722989B1 (fr) * 1994-07-29 1997-05-30 Synthelabo Utilisation de l'ifenprodil et de ses enantiomeres pour la preparation de medicaments utiles dans le traitement des neuropathies peripheriques et des maladies neurodegeneratives centrales
DK0777652T3 (da) * 1994-08-18 2003-10-20 Pfizer Neurobeskyttende 3-(piperidinyl-1)-chroman-4,7-diol-og 1-(4-hydrophenyl)-2-(piperidinyl-1)alkanolderivater
JPH08231400A (ja) * 1995-02-24 1996-09-10 Rohto Pharmaceut Co Ltd イフェンプロジルを必須成分とする眼圧降下剤
EP1024799A1 (en) 1997-10-24 2000-08-09 Warner-Lambert Company Method for treating disease-related or drug-induced dyskinesias
GB9804885D0 (en) 1998-03-06 1998-04-29 Merck Sharp & Dohme Therapeutic combination
OA12905A (en) 2002-08-19 2006-10-13 Pfizer Prod Inc Combination therapy for hyperproliferative diseases.
US20050037063A1 (en) * 2003-07-21 2005-02-17 Bolton Anthony E. Combined therapies
US20060063803A1 (en) * 2004-09-23 2006-03-23 Pfizer Inc 4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
RU2469023C1 (ru) * 2011-06-22 2012-12-10 Учреждение Российской академии наук Институт молекулярной генетики РАН (ИМГ РАН) Равномерно меченный тритием 4-[2-(4-бензилпиперидин-1-ил-гидроксипропил] фенол
MX2015014666A (es) 2013-04-17 2016-03-01 Pfizer Derivados de n-piperidin-3-ilbenzamida para tratar enfermedades cardiovasculares.
JP2017530195A (ja) 2014-10-03 2017-10-12 ラケシス・バイオサイエンシーズ・リミテッド 神経学的及び神経変性疾患及び障害を処置するための鼻腔投与組成物
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
EP3383429B1 (en) 2015-11-30 2020-10-14 INSERM - Institut National de la Santé et de la Recherche Médicale Nmdar antagonists for the treatment of tumor angiogenesis
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
WO2021209563A1 (en) 2020-04-16 2021-10-21 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1915334A (en) * 1930-10-16 1933-06-27 Du Pont Fluosilicate of organic heterocyclic bases and process of making it
US2075359A (en) * 1930-10-16 1937-03-30 Du Pont Insecticide

Also Published As

Publication number Publication date
FR5733M (cg-RX-API-DMAC7.html) 1968-01-22
GB1159449A (en) 1969-07-23
DE1695772A1 (de) 1972-02-17
US3509164A (en) 1970-04-28
DE1695772B2 (de) 1973-11-22
BE878876Q (fr) 1980-03-19

Similar Documents

Publication Publication Date Title
DE1695772C3 (de) l-(p-Hydroxyphenyl)-2-(4-benzylpiperidino)-propan-l-ol und Verfahren zu seiner Herstellung
DE2223184C3 (de) Benzofuranderivate und deren pharmazeutisch vertragliche Säureadditionssalze sowie ein Verfahren zu deren Herstellung und Arzneimittel mit einem Gehalt dieser Verbindungen
DE1468092B2 (de) Aminopropoxy-derivate des tetrahydronaphthalins und des indans, deren saeureadditionssalze, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische praeparate
DE2164636C3 (de) N-(Phenoxyalkyl)-a-methylphenäthylamine, Verfahren zu deren Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE2631885C2 (de) 1-(4-Phenoxyphenyl)-piperazin-Derivate, ihre Salze, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zubereitungen
DE3133814A1 (de) 2-(2-hydroxy-3'-(1,1-dimethylpropylamino)-propoxy)-w-phenylpropiophenon, dessen herstellung und i.v. und oral zu verabreichendes mittel gegen herzrhythmusstoerungen
DE2635961A1 (de) Therapeutisch wirksame verbindungen und verfahren zu ihrer herstellung
DE3204960A1 (de) Corynanthein-derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DE2632118C3 (de) Apovincaminolester und Verfahren zu deren Herstellung und Arzneimittel
DE2458638C2 (de) 4'-substituierte 2-Methyl-3-piperidinopropiophenonderivate, Verfahren zu deren Herstellung und pharmakologische Zubereitungen, welche diese enthalten
DE1470074B2 (de) 1,2,3,4,6,7-hexahydro-11bh-benzo eckige klammer auf a eckige klammer zu chinolizine sowie deren acetate und/oder physiologisch vertraegliche saeureadditionssalze sowie verfahren zu ihrer herstellung
DE2322313A1 (de) Pyrazolderivate und verfahren zu ihrer herstellung
DE2725245C2 (de) Methylaminderivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische oder veterinärmedizinische Zusammensetzungen
DE2858813C2 (cg-RX-API-DMAC7.html)
DE2829619A1 (de) Arzneimittel, enthaltend benzyliden- 2-benzofurane
DE2508251C2 (de) Derivate des Indols, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
DE2024049B2 (de) Alpha-(3,4-dihydroxyphenyl)-alpha(2-piperidinyl)-methanol
DE2942065A1 (de) Neue 1,6-naphthyridinderivate, verfahren zu ihrer herstellung sowie mittel gegen schwindel und zur verbesserung der zerebralen zirkulation, die diese derivate enthalten
DE2735570C2 (de) Isomere Terpenphenoxyalkylamine und pharmazeutische Zubereitung
DE2029000A1 (cg-RX-API-DMAC7.html)
DE1922280B2 (de) l-Methyl-5-(3'-dimethylaminopropyliden)-5Hdibenzo [a,d] -cyclohepten-N-oxid und dessen Säureadditionssalze, sowie Verfahren zu deren Herstellung und diese Verbindungen enthaltende Präparate
DE2733056C2 (de) Vincamenin und seine Säureadditionssalze, solche enthaltende Arzneimittel sowie Verfahren zur Herstellung der genannten Verbindungen
DE2113489B2 (de) 2-Nitro-benzofuranderivate, ein Verfahren zu deren Herstellung sowie diese Verbindungen enthaltende Arzneimittel
DE10131217A1 (de) 3-Phenyl-3,7-diazabicyclo 3,3,1 nonan-Verbindungen sowie Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
DE3028927A1 (de) Mittel, welche azoverbindungen enthalten

Legal Events

Date Code Title Description
C3 Grant after two publication steps (3rd publication)
E77 Valid patent as to the heymanns-index 1977
8339 Ceased/non-payment of the annual fee